Medullary Thyroid Carcinoma

Quick Answer

Medullary thyroid carcinoma (MTC) arises from parafollicular C cells, which do not express the sodium-iodide symporter — so radioiodine has no role (a common conceptual trap: the entire differentiated-thyroid-cancer RAI pathway is inapplicable). Management centers on complete surgical resection, with calcitonin and CEA kinetics (doubling times) driving surveillance and prognosis. For biochemical recurrence, functional imaging localizes disease — F-18-FDOPA is often the most sensitive, Ga-68-DOTATATE may guide PRRT, and FDG favors aggressive, short-doubling-time disease. RET testing is mandatory and enables selective RET-inhibitor therapy.

Background & Genetics

MTC secretes calcitonin (and CEA) from neuroendocrine C cells. It is sporadic (~75%) or hereditary (~25%) — MEN2A (with pheochromocytoma and primary hyperparathyroidism), MEN2B (with mucosal neuromas, marfanoid habitus, earlier/aggressive MTC), and familial MTC — all RET proto-oncogene-driven. Specific RET codons (e.g., M918T in MEN2B) predict aggressiveness and prophylactic-thyroidectomy timing.

Clinical & Laboratory

Thyroid nodule ± cervical nodes; diarrhea/flushing with high calcitonin. Calcitonin and CEA are the tumor markers; doubling times are the key prognostic/surveillance metric. In hereditary disease, screen for pheochromocytoma (plasma/urine metanephrines) BEFORE any neck surgery — an unrecognized pheo can precipitate intraoperative crisis.

Imaging by Scenario

• F-18-FDOPA PET/CT: often the most sensitive for localizing recurrent MTC, especially at moderate calcitonin levels.
• Ga-68-DOTATATE PET: variable SSTR expression; useful and may guide PRRT in selected SSTR-positive cases.
• FDG-PET/CT: favored in aggressive disease and short calcitonin/CEA doubling times (poor-prognosis marker).
• Neck ultrasound and CT/MRI for structural staging (liver MRI for hepatic metastases).

Interpretation & Decision

At biochemical recurrence, tracer choice tracks biology: FDOPA for general localization, DOTATATE to assess SSTR/PRRT candidacy, FDG when doubling times are short (aggressive). Multiple tracers are often complementary. RET status (germline for family screening; somatic for therapy) directs targeted treatment.

Differential Diagnosis

Differentiated (papillary/follicular) thyroid cancer (iodine-avid — the key contrast), C-cell hyperplasia, other neuroendocrine tumors, and anaplastic carcinoma. A non-iodine-avid thyroid malignancy should prompt consideration of MTC (calcitonin) or dedifferentiated DTC.

Reporting Checklist

• State that MTC is not iodine-avid (RAI inapplicable) when relevant.
• Report the tracer used and disease sites; correlate with calcitonin/CEA and doubling times.
• Note SSTR positivity (PRRT candidacy) on DOTATATE and FDG-avidity (aggressiveness).
• Recommend/confirm RET testing and, in hereditary disease, pheochromocytoma exclusion before surgery.

Common Pitfalls

• Attempting radioiodine work-up/therapy in MTC — no symporter, no mechanism.
• Relying on a single tracer; MTC imaging is often complementary (FDOPA + DOTATATE ± FDG).
• Operating before excluding pheochromocytoma in hereditary disease.
• Missing short doubling time as the flag for aggressive, FDG-avid disease.

Board Pearls

MTC arises from parafollicular C cells, which lack the sodium-iodide symporter — so radioiodine has no role (the entire DTC RAI pathway is inapplicable). Management is surgical, with calcitonin and CEA doubling times driving surveillance and prognosis. For recurrence, F-18-FDOPA is often the most sensitive localizer, Ga-68-DOTATATE may guide PRRT, and FDG favors aggressive, short-doubling-time disease. RET testing is mandatory and enables selective RET inhibitors (selpercatinib, pralsetinib).

Short calcitonin/CEA doubling time flags aggressive, often FDG-avid disease and poorer prognosis — pair FDG with the localizing tracers. SSTR expression is variable; DOTATATE positivity opens the PRRT option.

MTC is sporadic (~75%) or hereditary (MEN2A/2B, FMTC), all RET-driven — germline testing screens families and times prophylactic thyroidectomy. In hereditary disease, exclude pheochromocytoma before any neck operation (crisis risk). Imaging is frequently multi-tracer and complementary, matched to calcitonin level and doubling time.

Related Pages

• Tracers: DOTATATE, FDG; diseases: Neuroendocrine tumors, MEN syndromes.

Figure / Diagram Suggestions

• A tracer-by-biology decision aid (FDOPA localize / DOTATATE PRRT / FDG aggressive).
• A MEN2A vs MEN2B vs FMTC feature comparison.
• A doubling-time vs FDG-avidity prognostic schematic.

Self-Check